Alternatives to Exin Therapeutics

Generative AI drug discovery suite covering target ID, molecule design, biologics engineering and clinical trial prediction.

Physics-based simulation plus AI for molecular discovery across drug and materials design.

BenevolentAI applies a decade-built biomedical knowledge graph to drug target discovery and repurposing for biopharma R&D teams.

AI-CRISPR target discovery platform used by pharma partners to find causal immunology and oncology targets before committing to a program.

AI models that design peptide-LNP targeting systems to deliver genetic medicines to chosen cell types

Clinical-stage AI drug discovery company running a wet-and-dry lab-in-the-loop engine with 2M weekly experiments and a 50+ PB phenomics dataset

Evotec is a life-science partner running AI-assisted drug discovery and Just–Evotec Biologics manufacturing.

Clinical-stage biotech designing highly selective small-molecule drugs for oncology, immunology, and metabolic disease through partnership-led discovery.

Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.

Cloud ELN, LIMS, and AI platform that unifies biotech R&D data for discovery teams.

AI-native biotech pairing 20+ petabytes of cellular experiments with population genetics to find causal drug targets

Exscientia now lives inside Recursion — an AI drug discovery engine built on automated wet labs and a 50+ PB dataset.

An AI co-scientist that chains 150+ biological tools to run multi-omics, clinical genomics, and drug discovery analysis from plain-language prompts.

AI-driven scientific diligence for pharma BD, biotech, and life science investors evaluating in-licensing and M&A targets.

Open-source, self-hosted AI research assistant for drug discovery — molecular property prediction, virtual screening and PK/PD modeling on your own hardware.

Owkin's K Pro is an autonomous AI scientist agent that informs biopharma R&D, clinical trial and portfolio decisions.

Silico is Goodfire's interpretability agent for understanding, debugging, and controlling the internals of your AI models

Oncology real-world evidence platform turning patient data into AI-assisted cancer research insights.

All-in-human AI foundation models that predict brain activity and therapy response for CNS drug programs

Renamed: Deep 6 AI was acquired by Tempus AI in March 2025 and its trial matching folded into Tempus.

FDA-cleared AI for cancer pathology: prostate, breast, GI and pan-cancer detection on H&E slides, plus Virchow foundation models for research.

Cloud-based medical imaging platform that turns MRI, CT, and PET scans into regulatory-cleared quantitative imaging biomarkers.

Tempus is an AI precision oncology platform that pairs tumor DNA/RNA sequencing with a 7M+ de-identified clinical record library for treatment and trial

AI-guided protein engineering that co-optimizes binding, stability, activity, and expression using your own wet-lab data.

Cellino builds closed-loop, AI-guided bioprocessing hardware for personalized cell therapy manufacturing.

PathAI is an enterprise digital pathology platform for diagnostic accuracy and biopharma drug development.

Clinical-stage TechBio company using cellular imaging and AI to discover drugs, with a Phase 1 MALT1 inhibitor and a Genentech neuroscience collaboration.

Dotmatics Luma: agentic AI that plans, executes, and completes R&D data analysis, report generation and platform configuration for multimodal scientific

Automated cloud lab for protein validation — binding, expression, and thermostability assays from $149 per protein.

AI platform that designs and predicts molecular constructs for gene and RNA therapies before they reach the lab